114 results
Page 4 of 6
424B3
1av10z6v
28 Sep 21
Prospectus supplement
9:07am
8-K
o7dzn
28 Sep 21
Entry into a Material Definitive Agreement
8:53am
424B3
hzu jhcc0
13 Aug 21
Prospectus supplement
5:25pm
8-K
EX-99.1
065gkxcd
13 Aug 21
POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
7:00am
424B3
qzqyynks i7eqp
5 Aug 21
Prospectus supplement
4:26pm
424B3
nqnx9vv81xhj2a uy
9 Jun 21
Prospectus supplement
4:42pm
8-K
EX-99.1
umji5l xnd
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
8-K
4nymkz
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
425
2cpym
1 Jun 21
Business combination disclosure
4:30pm
425
EX-99.1
k4lf9fyaz i3
1 Jun 21
Business combination disclosure
4:30pm
CORRESP
ebrzuiia iw
3 May 21
Correspondence with SEC
12:00am
S-4/A
EX-10.7
an4t 12by5
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.16
nvcy3bwygjq
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
xpl cwq9tn45uu
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
hnx2cmnxt 6nu93i
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.14
2cshsm 1g8b
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm